Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EyePoint, Inc. (EYPT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, offering detailed insight into this clinical-stage biopharmaceutical company focused on serious retinal diseases. EyePoint’s filings, including multiple Form 8-K reports, document material events such as clinical milestones, equity offerings, and corporate actions related to its lead investigational product, DURAVYU™ (vorolanib intravitreal insert).
Through these filings, investors can review clinical development updates formally reported to the SEC, such as the completion of enrollment in the pivotal Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration, positive recommendations from the independent Data Safety Monitoring Committee, and the announcement of a pivotal Phase 3 program in diabetic macular edema (COMO and CAPRI). Filings also reference the posting of investor presentations that summarize estimated cash and investments and outline EyePoint’s development plans.
EyePoint’s SEC documents further detail capital markets activity, including an underwriting agreement and public offering of common stock and pre-funded warrants, as well as a Controlled Equity Offering Sales Agreement for at-the-market issuances. These filings describe the terms of offerings, net proceeds, intended use of funds to advance DURAVYU in wet AMD and DME, and the legal opinions related to the validity of issued securities.
Additional filings cover corporate governance and compensation matters, such as amendments to the 2023 Long-Term Incentive Plan, inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4), and the results of stockholder votes at the annual meeting. Risk factors and forward-looking statement sections referenced in filings highlight regulatory interactions, including an FDA warning letter pertaining to EyePoint’s Watertown manufacturing facility and an August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts.
On Stock Titan, EyePoint’s SEC filings are paired with AI-powered summaries that help explain the significance of each document, from 8-K current reports to registration-related filings. This allows readers to quickly understand how new offerings, clinical disclosures, or governance changes may relate to EyePoint’s development of DURAVYU and its broader ophthalmic pipeline, while still having direct access to the full text of each filing as made available through EDGAR.
EyePoint, Inc. reported that the first patients have been dosed in COMO and CAPRI, its two global Phase 3 trials of DURAVYU for diabetic macular edema. These randomized, aflibercept-controlled studies each plan to enroll about 240 patients and use a six‑month redosing schedule.
DURAVYU is an investigational sustained-release tyrosine kinase inhibitor designed to target both VEGF-driven vascular leakage and IL‑6–mediated inflammation. EyePoint also highlighted fully enrolled Phase 3 wet AMD trials with topline data expected in mid‑2026 and DME Phase 3 topline results anticipated in the second half of 2027.
The company’s March 2026 investor presentation notes approximately $300M in cash and investments, which it expects to fund operations into the fourth quarter of 2027, and describes commercial manufacturing scale-up in Massachusetts to support a potential DURAVYU launch.
EyePoint, Inc. Schedule 13G discloses that Paradigm-related reporting persons hold disclosed stakes in EyePoint's common stock as of the close of business on
The filing shows Paradigm BioCapital Advisors (and related entities) with 4,192,261 shares (
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions. On February 17, 2026, he exercised stock options and acquired 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares in an open-market transaction at $15.00 per share. Following these moves, he reported holding 85,313 stock options and no directly held common shares from this transaction. A disclosed option award vests 25% on January 3, 2026, with the remainder vesting monthly over the next three years.
Eyepoint, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II and Chen Yu reporting beneficial ownership of 3,572,335 shares of common stock, representing 4.3% of the class based on 82,787,220 shares outstanding as of October 30, 2025.
The reporting persons indicate they share voting and dispositive power over these shares through the fund structure and related entities, while disclaiming group status and beneficial ownership beyond their pecuniary interest. They also certify the holdings are passive and not intended to change or influence control of Eyepoint.
Adage Capital Management, L.P. and related parties report a 5.68% beneficial stake in EyePoint, Inc. common stock. They collectively hold 4,700,000 shares with shared voting and dispositive power and no sole authority. The percentage is based on 82,787,220 shares outstanding as of October 30, 2025.
The filing is made on Schedule 13G/A, indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control of EyePoint. The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross.
On January 6, 2026, EyePoint, Inc. director Nancy Lurker acquired 75,133 shares of common stock at $0.00 per share upon the vesting and settlement of previously granted restricted stock units. These units were part of an award that vests in three equal annual installments beginning January 6, 2024.
Following this transaction, she directly owned 294,346 shares of EyePoint common stock. An additional 126,889 shares are held indirectly by a family trust for the benefit of her children, for which her spouse is trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. President and CEO Jay S. Duker, who also serves as a director, reported routine equity activity on January 6, 2026 related to previously granted restricted stock units. A block of 20,793 restricted stock units converted into the same number of shares of common stock at an exercise price of $0.00, reflecting vesting of his equity award. To cover taxes on this vesting, 10,054 shares of common stock were withheld by EyePoint at a price of $16.86, and the filing specifies that no shares were sold in the market. After these transactions, Duker directly held 77,752 shares of common stock, and an additional 99,165 shares were reported as indirectly held by a family trust for the benefit of his children, for which he disclaims beneficial ownership.
EyePoint, Inc.’s Chief Financial Officer, Elston George, reported equity compensation activity involving restricted stock units and common shares. On January 6, 2026, 15,285 restricted stock units converted into 15,285 shares of common stock at an exercise price of $0.00, increasing his directly held common shares before withholding to 96,339.
On the same date, 4,487 of those common shares were withheld by the issuer at $16.86 per share to satisfy tax withholding obligations, rather than being sold in the market, leaving 91,852 common shares held directly. An additional 25,000 common shares are reported as held indirectly in a family trust for the benefit of his children, with the trust company as trustee and George disclaiming beneficial ownership of those securities.
EyePoint, Inc. Chief Medical Officer Ribeiro Ramiro reported exercising stock options and selling company shares. On January 5, 2026, Ramiro exercised an option to buy 29,250 shares of common stock at $8.26 per share, increasing his directly held common stock to 42,544 shares. That same day, he reported selling 42,544 shares of common stock at a weighted average price of $17.0957 per share, leaving him with no directly held common stock after the transactions.
Ramiro continues to hold 87,750 stock options following the reported activity. According to the filing, the option vests with 25% on January 3, 2026, with the remaining portion vesting monthly over the next three years, and carries an expiration date of January 3, 2035. The weighted average sale price reflects multiple trades between $16.68 and $17.51.
EyePoint, Inc. filed a current report to let investors know it has released a press release with preliminary cash information as of December 31, 2025 and other corporate updates. The company notes that these figures are preliminary, unaudited and may change once full audited financial statements for the year are completed. The press release is included as Exhibit 99.1, allowing the disclosed preliminary cash position and corporate developments to be incorporated by reference in future securities offerings or other SEC filings.